Rational Design of Frontline Institutional Phage Cocktail for the Treatment of Nosocomial Enterobacter cloacae Complex Infections

Dinesh Subedi,Fernando L Gordillo Altamirano,Rylee Deehan,Avindya Perera,Ruzeen Patwa,Xenia Kostoulias,Denis Korneev,Luke Blakeway,Nenad Macesic,Anton Y L Peleg,Jeremy J Barr

DOI: https://doi.org/10.1101/2024.06.30.601436

2024-07-03

Abstract:Phage therapy is a promising strategy to treat antimicrobial-resistant infections. Currently, phage therapy applications span personalised treatments that are tailored for a given patients infection, through to the use of pre-established cocktails of virulent phages against clinically relevant pathogens. However, both approaches face challenges, with personalised phage therapy being time-consuming and requiring a phage match to a patients infection, while phage cocktails may not be effective against a patients specific strain. The Alfred Hospital in Melbourne, Australia has reported an ongoing outbreak of infections by the Enterobacter cloacae complex (ECC), a group of emerging multidrug-resistant pathogens responsible for considerable morbidity and mortality. Utilising the hospitals strain collection, built over the last decade, we established an initial three-phage product with 54% ECC coverage that effectively reduced bacterial loads (>99%) in septicaemic mice. We then iteratively improved this product by enhancing phage killing efficiency using phage training and expanded host range through targeted phage isolation against low-coverage ECC strains. This iterative optimisation led to the creation of the product Entelli-02, containing five well characterised virulent phages that target clinical ECC strains through distinct bacterial cell surface receptors. Importantly, Entelli-02 exhibits broad host coverage (99%) and efficacy (92%) against The Alfred Hospital ECC strain collection (n = 156). We produced this as a therapeutic-grade product, verified and endotoxin unit compliant, ready for use. This approach integrated academic phage research with clinical insights to produce the phage product Entelli-02 as an institution-specific phage cocktail with frontline efficacy and on-demand availability.

Microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the nosocomial infection problem caused by a multi - drug - resistant bacterium, Enterobacter cloacae complex (ECC), in The Alfred Hospital in Melbourne, Australia. Specifically, the paper aims to develop an effective phage product (phage cocktail) to deal with the infections caused by this multi - drug - resistant bacterium. Since these bacteria are highly drug - resistant and contagious, the effectiveness of traditional antibiotic treatment is limited, so new treatment methods need to be found. Through screening and optimizing phage combinations, the paper finally developed a phage product named Entelli - 02, which can effectively cover and kill ECC strains in the hospital.

### Main research contents of the paper:
1. **Screening and characterization of phages**:
- 21 new phages were screened from 206 clinical ECC strains, and genomic sequencing and classification were carried out on these phages.
- Three phages (øEnA02, øEnC07, and øEnC15) were selected to form a preliminary phage combination (cocktail - V1), and these phages have a wide host range and high antibacterial efficacy.

2. **Stability test of phages**:
- The stability of phages under different storage conditions was tested. The results showed that the phages still maintained high activity after being stored at 4°C for 30 months.

3. **Identification of phage receptors**:
- By generating phage - resistant mutants and performing gene sequencing, the receptors of each phage were determined. The results showed that these three phages target different subunits of LPS respectively, which helps to reduce the generation of phage resistance.

4. **In - vivo effectiveness evaluation of the preliminary phage combination**:
- The in - vivo efficacy of cocktail - V1 was evaluated using a mouse model. The results showed that the phage combination could significantly reduce the bacterial load in the blood, kidneys, liver and spleen of infected mice, and the phages could effectively replicate and spread in mice.

5. **Phage training to improve adaptability and infectivity**:
- Phages were trained by the method of experimental evolution to improve their infectivity and lysis ability to specific hosts. After training, the infection efficiency of phages was significantly improved.

6. **Expanding the host range of the phage combination**:
- In order to further improve the broad - spectrum antibacterial ability of the phage combination, the researchers increased the infectivity to ECC strains with low coverage by directional isolation of phages, and finally formed the Entelli - 02 product containing five phages.

### Conclusion:
The paper successfully developed a phage product named Entelli - 02, which has a wide host coverage range (99%) and high antibacterial ability (92%), and can effectively deal with ECC infections in The Alfred Hospital. This research result provides a new treatment strategy for dealing with multi - drug - resistant bacterial infections.